Medical device maker Insulet has granted the underwriters the right to purchase up to an additional 734,759 shares to cover over-allotments, if any. Insulet will not receive any proceeds from the sale of shares by the selling stockholders.
JP Morgan Securities and Merrill Lynch, Pierce, Fenner & Smith will serve as joint book-running managers, and Leerink Swann & Co, Thomas Weisel Partners and Canaccord Adams will serve as co-managers for the proposed offering.